0001847416 false 0001847416 2023-04-24 2023-04-24 0001847416 ORIA:UnitsEachConsistingOfOneClassOrdinaryShare0.0001ParValueAndOnefifthOfOneRedeemableWarrantMember 2023-04-24 2023-04-24 0001847416 ORIA:ClassOrdinarySharesParValue0.0001PerShareMember 2023-04-24 2023-04-24 0001847416 ORIA:RedeemableWarrantsIncludedAsPartOfUnitsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2023-04-24 2023-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 24, 2023

 

Orion Biotech Opportunities Corp.

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-40410   98-1583924
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

One Vanderbilt Avenue, 26th Floor

New York, NY

  

 

10017

(Address of principal executive offices)   (Zip Code)

 

(212) 303-1650
(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant   ORIAU   The Nasdaq Stock Market LLC
Class A ordinary shares, par value $0.0001 per share   ORIA   The Nasdaq Stock Market LLC
Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   ORIAW   The Nasdaq Stock Market LLC

 

 

 

 

 

 

Item 8.01. Other Events.

 

On April 24, 2023, Orion Biotech Opportunities Corp. (the “Company”) issued a press release announcing that as of the close of business on May 17, 2023, the publicly held Class A ordinary shares, par value $0.0001, will be deemed cancelled and will represent only the right to receive their pro-rata share in the Company’s trust account, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association.

 

The Company’s sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company’s initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless.

 

The Company will file a Form 25 with the Commission in order to delist the Company’s securities. The Company thereafter expects to file a Form 15 with the Commission to terminate the registration of the Company’s securities under the Securities Exchange Act of 1934, as amended.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated April 24, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ORION BIOTECH OPPORTUNITIES CORP.
     
Date: April 24, 2023 By: /s/ Mark Kayal
  Name: Mark Kayal
  Title: Chief Financial Officer

 

 

2
 

Orion Biotech Opportunit... (NASDAQ:ORIA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Orion Biotech Opportunit....
Orion Biotech Opportunit... (NASDAQ:ORIA)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Orion Biotech Opportunit....